Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Elliott B, Briggs A

Connect to this object online.

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States by Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A

Connect to this object online.

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia by Tremblay G, Dolph M, Bhor M, Said Q, Roy A, Elliott B, Briggs A

Connect to this object online.